MedTrace Logo

HELIO Liver Test Performance Study in China (HEPATIC)

NCT05053412 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1556

Last updated 2024-08-02

No results posted yet for this study

Summary

De-identified whole blood and serum samples are collected for the purpose of evaluating the performance (sensitivity/specificity) of the HelioLiver Test for the detection of hepatocellular carcinoma (HCC).

Conditions

  • Hepatocellular Carcinoma and Liver Disease

Interventions

DIAGNOSTIC_TEST

Helio Liver Test

A Helio Liver Test is used as the basis of performance evaluation for specificity and sensitivity for all patients enrolled in the study.

Sponsors & Collaborators

  • Helio Health Inc., Irvine, CA

    collaborator UNKNOWN

  • Helio Genomics

    lead INDUSTRY

Principal Investigators

  • RIchard Van Etten, MD, PhD · University of California, Irvine

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2024-03-01
Completion
2024-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05053412 on ClinicalTrials.gov